Eureka Therapeutics, Inc.

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative technology platforms to access cancer-specific targets and harness the evolutionary power of T cells for the treatment of solid tumors and other malignancies.

Products & Services

E-ALPHA® Phage Display Platform:Leverages high-throughput screening to develop cancer-specific antibodies.

ARTEMIS® Cell Receptor Platform:Harnesses the evolutionary power of T cells to fight cancer.

ARTEMIS® T-Cell Therapy:A therapy utilizing T cells to target and treat cancer, with ongoing clinical trials.

Specialties

Cancer-specific antibodies T-cell therapy Solid tumor treatment Clinical-stage drug development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 10600000 MR: - FA: 10.6 million FAN: 10600000	D: 2023-06-06 FD: 2023-06-06	1 investors

Grant Latest

2023-06-06

$10.6M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Cheng Liu

Founder, President & CEO

V

Vivien Chan

COO

V

Victor Shum

General Counsel & CBO

P

Pei Wang

Senior Vice President, Clinical Development and CMC

J

Jacqueline Northcut

Director

S

Sandy Chau

Director

View 11 more team members with Pro

Unlock Full Team Directory

Recent News